3 completed, 2 active not recruiting, 2 recruiting, 2 unknown. 7 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
Follow Relapsed Ovarian Cancer: new trials by email Literature Review of Relapsed Ovarian Cancer trials Research Report on Relapsed Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib, Apatinib - Relapsed Ovarian Cancer | Phase 2 | Not yet recruiting | Jin Li | 54 | 2023-10-30 | 2023-10-13 |
| Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Carboplatin - Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Recruiting | University College, London | 80 | 2023-05-24 | 2024-04-12 |
| Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib+Apatinib, Fluzoparib Monotherapy - Relapsed Ovarian Cancer | Phase 2 | Unknown | Xiaohua Wu MD | 132 | 2022-08-01 | 2022-07-29 |
| OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC OSE2101, Pembrolizumab 25 MG/ML [Keytruda] - Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Active not recruiting | ARCAGY/ GINECO GROUP | 180 | 2021-08-05 | 2024-12-02 |
| A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer AK112 low dose, AK112 medium dose, AK112 high dose - Ovarian Neoplasms, Recurrent Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | Akeso | 8 | 2021-06-24 | 2024-01-05 |
| Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial Secondary cytoreduction, Chemotherapy - Relapsed Ovarian Cancer | Not applicable | Recruiting | Women's Hospital School Of Medicine Zhejiang University | 400 | 2021-05-01 | 2022-11-07 |
| A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients Fluzoparib+Apatinib, Fluzoparib - Relapsed Ovarian Cancer | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2020-10-16 | 2025-02-24 |
| Reprab Study: PLD + Trabectedin Rechallenge PLD and Trabectedin rechallenge - Relapsed Ovarian Cancer | Phase 2 | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 64 | 2020-10-01 | 2021-08-09 |
| Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Olaparib 300mg tablets - Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy | Phase 3 | Completed | AstraZeneca | 229 | 2018-05-29 | 2025-07-10 |
| Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients trabectedin - Relapsed Ovarian Cancer | Completed | PharmaMar | 220 | 2015-07-28 | 2021-10-29 | |
| Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Olaparib 300mg tablets, Placebo to match olaparib 300mg - Platinum Sensitive, BRCA Mutated | Phase 3 | Active not recruiting | AstraZeneca | 327 | 2013-09-03 | 2026-07-29 |
Ovarian Neoplasms (11) · Carcinoma, Endometrioid (1) · Fallopian Tube Neoplasms (1) · Recurrence (1)
Adnexal Diseases (11) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genital Diseases (11) · Genital Diseases, Female (11) · Genital Neoplasms, Female (11) · Gonadal Disorders (11) · Neoplasms (11) · Neoplasms by Site (11) · Ovarian Diseases (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Adenocarcinoma (1)
fluzoparib (2) · olaparib (2) · 1-dodecylpyridoxal (1) · Carboplatin (1) · Drug Therapy (1) · Trabectedin (1) · apatinib (1) · pembrolizumab (1)
AstraZeneca (2) · ARCAGY/ GINECO GROUP (1) · Akeso (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Jin Li (1) · PharmaMar (1) · University College, London (1) · Women's Hospital School Of Medicine Zhejiang University (1) · Xiaohua Wu MD (1)
China (5) · Belgium (3) · France (3) · Germany (3) · Italy (3) · Spain (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Israel (1) · Japan (1) · Malaysia (1) · Netherlands (1) · Poland (1)
Ding MA, PhD (1) · Lingying Wu, MD (1) · Professor E Pujade-Lauraine, MD, PhD (1) · Xiaohua Wu, Ph.D., MD (1)
PMID 28754483, PMID 30026002, PMID 32977221, PMID 33743851, PMID 35131903, PMID 35170751, PMID 35772665, PMID 38159938, PMID 38755585, PMID 39155847, PMID 39695768, PMID 39806715, PMID 41861615